Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.61 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13151156 | 0.83 | DDB1 (0.44) | DDB1CRBNMEN1KMT2AALOX5 | |
| SCHEMBL7344849 | 0.82 | ALOX5 (0.59) | MAPTALDH1A1MEN1KMT2AALOX5 | |
| SCHEMBL5056229 | 0.82 | ALOX5 (0.50) | DDB1CRBNMAPTALDH1A1MEN1 | |
| SCHEMBL1787047 | 0.81 | ALDH1A1 (0.51) | DDB1CRBNALDH1A1MEN1KMT2A | |
| SCHEMBL150081 | 0.81 | ALOX5 (0.60) | MAPTMEN1KMT2AALOX5ADRB1 | |
| SCHEMBL5182221 | 0.81 | FAAH (0.47) | DDB1CRBNMAPTMEN1KMT2A | |
| SCHEMBL13853418 | 0.80 | CYP2C9 (0.45) | DDB1CRBNMAPTALDH1A1MEN1 | |
| SCHEMBL27945523 | 0.79 | HTR1A (0.54) | DDB1CRBNALDH1A1ALOX5CYP3A4 | |
| Hydrochloric Acid SCHEMBL3950851 | 0.79 | CYP2C9 (0.44) | DDB1CRBNMAPTALDH1A1MEN1 | |
| SCHEMBL146714 | 0.79 | NPC1 (0.56) | DDB1CRBNMAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2334637-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-8372840-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2013-02-12 | — | — | US | disclosed |
| EP-2334637-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | Xention Limited (GB) | 2011-06-22 | — | — | EP | disclosed |
| US-20100087438-A1 | New Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| WO-2010023446-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| WO-2009122180-A1 | PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES | MEDICAL RESEARCH COUNCIL (GB) | 2009-10-08 | — | — | WO | disclosed |
| US-7288559-B2 | Carboxamide spirohydantoin CGRP receptor antagonists | MERCK + CO, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288559-B2 | Carboxamide spirohydantoin CGRP receptor antagonists | MERCK + CO, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070111982-A1 | Calcitonin Gene-Related Peptide, CGRP; treatment of migraine and cluster headache; 2,5-dioxo-3',4'-dihydro-spiro(imidazolidine-4,2'(1'H)-naphthalene)-6'-carboxamides | MERCK SHARP & DOHME LLC | 2007-05-17 | — | — | US | disclosed |
| US-20070111982-A1 | Calcitonin Gene-Related Peptide, CGRP; treatment of migraine and cluster headache; 2,5-dioxo-3',4'-dihydro-spiro(imidazolidine-4,2'(1'H)-naphthalene)-6'-carboxamides | MERCK SHARP & DOHME LLC | 2007-05-17 | — | — | US | disclosed |
| WO-2006114371-A1 | NOVEL COMPOUNDS FOR TREATING INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-02 | — | — | WO | disclosed |
| EP-0675172-B1 | Water-solable azo compounds, process for their preparation and their use as dyestuffs | DYSTAR TEXTILFARBEN GMBH & CO (DE) | 2001-04-11 | — | — | EP | disclosed |
| US-5539088-A | PROVIDE DYEINGS IN BRILLIANT SHADES WITH GOOD FASTNESS PROPERTIES AND HIGH DEGREE OF FIXATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087438-A1 | New Potassium Channel Blockers | KCNJ2, KCNB1, KCNJ11 | DDB1 3518/4885CRBN 2871/4885ADRA2C 269/4885 |
| US-20100056524-A1 | Compound | NR3C2, NR3C1, NR2E3 | DDB1 4388/4885CRBN 469/4885ADRA2C 382/4885 |
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | DDB1 3920/4885CRBN 927/4885ADRA2C 627/4885 |
| US-20070111982-A1 | Calcitonin Gene-Related Peptide, CGRP; treatment of migraine and cluster headache; 2,5-dioxo-3',4'-dihydro-spiro(imidazolidine-4,2'(1'H)-naphthalene)-6'-carboxamides | CALCA, CALCRL, CALCB | DDB1 1450/4885CRBN 1503/4885ADRA2C 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.